Determining cell-type abundance and expression from bulk tissues with digital cytometry
By Aaron M. Newman, C. Steen, C. Liu, Andrew J. Gentles, Aadel A Chaudhuri, F. Scherer, M. Khodadoust, M. S. Esfahani, Bogdan Luca, D. Steiner and 2 more. Nature Biotechnology, 2019
3,625 citations recorded by the source corpus.
Single-cell RNA-sequencing has emerged as a powerful technique for characterizing cellular heterogeneity, but it is currently impractical on large sample cohorts and cannot be applied to fixed specimens collected as part of routine clinical care. We previously developed an approach for digital cytometry, called CIBERSORT, that enables estimation of cell type abundances from bulk tissue transcriptomes. We now introduce CIBERSORTx, a machine learning method that extends this framework to infer cell-type-specific gene expression profiles without physical cell isolation. By minimizing platform-specific variation, CIBERSORTx also allows the use of single-cell RNA-sequencing data for large-scale tissue dissection. We evaluated the utility of CIBERSORTx in multiple tumor types, including melanoma, where single-cell reference profiles were used to dissect bulk clinical specimens, revealing cell-type-specific phenotypic states linked to distinct driver mutations and response to immune checkpoint blockade. We anticipate that digital cytometry will augment single-cell profiling efforts, enabling cost-effective, high-throughput tissue characterization without the need for antibodies, disaggregation or viable cells. CIBERSORTx, a suite of computational tools, enables inference of cell type abundance and cell-type-specific gene expression profiles from bulk RNA profiles.
Subfields: Biophysics, Cancer Research, Molecular Biology
View Paper: https://www.semanticscholar.org/paper/f76a37c32a76238960691353b1305cbfb36742a1
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Biophysics
In Molecular Biology
Citations in the corpus
- Deep learning in cancer diagnosis, prognosis and treatment selection (2021, neutral): “using transcriptomic [141, 142] or methylation data [143].”
- Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities (2021, methodology): “CIBERSORT deconvolution—Immune cell deconvolution of the RNAseq data was performed with CIBERSORTx (Newman et al., 2015; Newman et al., 2019), run in absolute mode using the LM22 signature over 1000 permutations.”
- From patterns to patients: Advances in clinical machine learning for cancer diagnosis, prognosis, and treatment. (2023, background): “78,79 While most deconvolution efforts have thus far focused on bulk cellular tissue sources such as tumor specimens, ML deconvolution applications to cell-free nucleic acids are emerging.”